Literature DB >> 21334392

Hepatitis C virus RNA recombination in cell culture.

Jochen Reiter1, Gemma Pérez-Vilaró, Nicoletta Scheller, Leonardo Bruno Mina, Juana Díez, Andreas Meyerhans.   

Abstract

BACKGROUND & AIMS: The Hepatitis C virus (HCV) exhibits large genetic diversity, both on a global scale and at the level of the infected individual. A major underlying mechanism of the observed sequence differences is error-prone virus replication by the viral RNA polymerase NS5B. In addition, based on phylogenetic comparisons of patient-derived HCV sequences, there is evidence of HCV recombination. However, to date little is known about the frequency by which recombination events occur in HCV and under what conditions recombination may become important in HCV evolution. We, therefore, aimed to set up an experimental model system that would allow us to analyze and to characterize recombination events during HCV replication.
METHODS: A neomycin-selectable, HCV replicon-based recombination detection system was established. HCV replicons were mutated within either the neomycin-phosphotransferase gene or the NS5B polymerase. Upon co-transfection of hepatic cells lines, recombination between the mutated sites is necessary to restore the selectable phenotype.
RESULTS: Recombinants were readily detected with frequencies correlating to the distance between the mutations. The recombinant frequency normalized to a crossover range of one nucleotide was around 4 × 10(-8).
CONCLUSIONS: An experimental system to select for HCV recombinants in cell culture was successfully established. It allowed deriving first estimates of recombinant frequencies. Based on these, recombination in HCV seems rare. However, due to the rapid virus turnover and the large number of HCV-infected liver cells in vivo, it is expected that recombination will be of biological importance when strong selection pressures are operative.
Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21334392     DOI: 10.1016/j.jhep.2010.12.038

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  8 in total

1.  Chimeric rhinoviruses obtained via genetic engineering or artificially induced recombination are viable only if the polyprotein coding sequence derives from the same species.

Authors:  Manuel Schibler; Isabelle Piuz; Weidong Hao; Caroline Tapparel
Journal:  J Virol       Date:  2015-02-04       Impact factor: 5.103

2.  Analysis of the evolution and structure of a complex intrahost viral population in chronic hepatitis C virus mapped by ultradeep pyrosequencing.

Authors:  Brendan A Palmer; Zoya Dimitrova; Pavel Skums; Orla Crosbie; Elizabeth Kenny-Walsh; Liam J Fanning
Journal:  J Virol       Date:  2014-09-17       Impact factor: 5.103

3.  High recombination rate of hepatitis C virus revealed by a green fluorescent protein reconstitution cell system.

Authors:  Andrea Galli; Ulrik Fahnøe; Jens Bukh
Journal:  Virus Evol       Date:  2021-12-23

Review 4.  Why do RNA viruses recombine?

Authors:  Etienne Simon-Loriere; Edward C Holmes
Journal:  Nat Rev Microbiol       Date:  2011-07-04       Impact factor: 60.633

Review 5.  Recombination in hepatitis C virus.

Authors:  Fernando González-Candelas; F Xavier López-Labrador; María Alma Bracho
Journal:  Viruses       Date:  2011-10-24       Impact factor: 5.048

6.  Feature Learning of Virus Genome Evolution With the Nucleotide Skip-Gram Neural Network.

Authors:  Hyunjin Shim
Journal:  Evol Bioinform Online       Date:  2019-01-10       Impact factor: 1.625

7.  Productive homologous and non-homologous recombination of hepatitis C virus in cell culture.

Authors:  Troels K H Scheel; Andrea Galli; Yi-Ping Li; Lotte S Mikkelsen; Judith M Gottwein; Jens Bukh
Journal:  PLoS Pathog       Date:  2013-03-28       Impact factor: 6.823

8.  Assessing parallel gene histories in viral genomes.

Authors:  Beatriz Mengual-Chuliá; Stéphanie Bedhomme; Guillaume Lafforgue; Santiago F Elena; Ignacio G Bravo
Journal:  BMC Evol Biol       Date:  2016-02-05       Impact factor: 3.260

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.